Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Tvardi Therapeutics, Inc.

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
From Tvardi Therapeutics, Inc.
Via Business Wire
Tickers TVRD
Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
Tickers TVRD
Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Present at the 8th Annual IPF Summit
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate at the 2024 BTIG Virtual Biotechnology Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate at the Cowen 44th Annual Health Care Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces Presentation of REVERT LIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Idiopathic Pulmonary Fibrosis Trial using TTI-101, a Novel STAT3 Inhibitor
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 Inhibitor
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate at the Cowen 43rd Annual Health Care Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Announces First Patients Dosed in Phase 2 Trial of TTI-101 in Metastatic Breast Cancer
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Present at the Guggenheim Securities Oncology Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics to Participate in Morgan Stanley Private Company Biotech Corporate Access Day
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma
From Tvardi Therapeutics, Inc.
Via Business Wire
Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to Be Presented at the 2022 Annual Meeting of the American Association for Cancer Research
From Tvardi Therapeutics, Inc.
Via Business Wire
Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs
From Tvardi Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.